Symtuza is a combination medication that treats human immunodeficiency virus (HIV). It's a tablet that contains three antiretroviral (ARV) medications — darunavir, emtricitabine, and tenofovir alafenamide — and a "booster" that helps the ARVs work better against the virus called cobicistat . Symtuza, also known as DRV/c/TAF/FTC, is a complete therapy for people with HIV weighing at least 88 pounds. It's taken once daily with food. Some common side effects of Symtuza include nausea and diarrhea.
Symtuza is a combination of four active ingredients that work together to treat HIV.
The following side effects may get better over time as your body gets used to the medication. Let your healthcare provider know immediately if you continue to experience these symptoms or if they worsen over time.
Contact your healthcare provider immediately if you experience any of the following.
Side effects that you should report to your care team as soon as possible:
Side effects that usually do not require medical attention (report these to your care team if they continue or are bothersome):
Symtuza was approved by the FDA for treating HIV in July 2018. It's approved for people weighing at least 88 pounds who either have never received HIV treatment before or have an HIV viral load of less than 50 copies/mL from a previous HIV treatment regimen.
People who took Symtuza in clinical studies didn't report weight gain as a side effect. But darunavir, one of the active ingredients in Symtuza, can cause fat buildup in the back of the neck, breast, and around the middle of the body. This might cause a change in weight. Talk to your healthcare team if you're concerned about this side effect or notice any concerning weight changes while you're taking Symtuza.
Yes. Some people who've taken Symtuza have had higher cholesterol and triglyceride levels. Your prescriber might recommend that you take cholesterol medications to manage this side effect if your cholesterol and triglyceride levels seem too high on your blood test results. Keep in mind that Symtuza can interact with statins, a common type of cholesterol medication, and raise your risk for serious muscle pain and muscle damage. Let your care team know if you have a history of high cholesterol so they can discuss with you about how to manage your cholesterol while you're taking Symtuza.
It's probably best not to crush the Symtuza tablet. But the manufacturer says that you can split the tablet in half with a pill cutter. If you have a hard time swallowing the tablet whole, taking two smaller pieces of the tablet might be easier for you. Make sure to take the entire dose right away after splitting the tablet. Ask your pharmacist or HIV specialist if you have any questions about taking the Symtuza tablet.
Biktarvy and Symtuza are both once-daily HIV treatment options. They're both combination medications that contain multiple antiretrovirals in a single tablet. Biktarvy contains bictegravir, emtricitabine, and tenofovir alafenamide. On the other hand, Symtuza contains darunavir, emtricitabine, tenofovir alafenamide, and cobicistat (which acts as a "booster" to help the HIV medication work better). Biktarvy is a first-choice treatment option for HIV. Symtuza is also a recommended treatment option but typically in certain situations only. Talk to your HIV specialist to compare between the two medications more and discuss which is a better option for you.
Talk to your prescriber first before you take Symtuza if you're allergic to medications that have sulfa, such as furosemide (Lasix), Bactrim (sulfamethoxazole / trimethoprim), or glipizide. This is because darunavir, one of the active ingredients in Symtuza, is also a sulfa drug. Taking Symtuza when you have a sulfa allergy can raise your risk of an allergic reaction. Let your healthcare team know about all the allergies you have so they can double check that Symtuza is safe for you to take. Get medical help if you experience itching, skin rash, redness, or swelling while you're taking Symtuza.
It's best not to drink alcohol while you're taking Symtuza. Drinking alcohol, especially in large amounts, can cause liver damage. Symtuza itself might raise your risk for serious liver problems, such as fat buildup in the liver, or lactic acid buildup in the blood. Drinking alcohol while you're taking Symtuza can raise these risks even further. Talk with your healthcare team right away if you have any signs and symptoms of liver damage, such as upper right-sided stomach pain, yellowing of the skin or whites of the eyes, or dark urine. Also, let your healthcare team know if you have symptoms of lactic acid buildup, such as weakness, muscle pain, and rapid breathing.
Some people who've taken Symtuza have developed kidney damage that might affect kidney function. Signs of kidney damage on blood test results can appear as early as 2 weeks after starting treatment. To lower the risk of harm, make sure to avoid other medications that potentially cause kidney damage, such as ibuprofen (Advil) and naproxen (Aleve), while you're taking Symtuza. Get your blood work done routinely so that the team can make sure Symtuza is safe for your kidney health. Let your prescriber know if you notice any unusual swelling, tiredness, weakness, or changes in urination because these can be symptoms of kidney problems.
Symtuza can cause some serious health issues. This risk may be even higher for certain groups. If this worries you, talk to your doctor or pharmacist about other options.
Before you start Symtuza, your healthcare team will check whether you're infected with the hepatitis B virus (HBV). This is because HBV can sometimes worsen if you take Symtuza and then stop the medication. This is also known as a hepatitis B flare. In some cases, it's led to a sudden worsening of liver function or liver failure.
If you have HBV and HIV, don't stop taking Symtuza without talking with your healthcare team first. Make sure to get your refills on time so that your treatment isn't interrupted. If you need to stop taking the medication, your healthcare team will continue to follow up with you for several months after you stop treatment. Your healthcare team will order blood work to check your liver for a hepatitis B flare.
In some rare cases, people who take medications containing NRTIs, such as Symtuza, have had liver problems. These liver problems can include a buildup of fat in the liver, leading to swelling and inflammation of the liver. Symtuza can also cause a buildup of lactic acid in the blood (lactic acidosis). Both conditions can be life-threatening.
Make sure to get the blood tests that your prescriber recommended as you continue treatment. These blood tests help your care team check for harmful effects on the liver and make sure Symtuza is still safe to take.
Talk with your healthcare team right away if you have signs and symptoms of liver damage, such as upper right-sided stomach pain, yellowing of the skin or whites of the eyes, or dark urine. Also let your care team know if you have symptoms of lactic acidosis, such as weakness, confusion, muscle pain, and rapid breathing.
Symtuza, specifically the darunavir component of the combination medication, can sometimes cause rash and other severe skin reactions. In studies, some people developed a mild or moderate rash within the first 4 weeks of treatment.
If you develop a mild or moderate rash while you're taking Symtuza, continue taking the medication and let your healthcare team know. Oftentimes, the rash goes away on its own. But if you develop a severe rash or if your rash gets worse, talk with your care team right away. Stop taking Symtuza and get medical help right away if you have a severe rash with fever, general discomfort, muscle or joint pain, mouth sores, blisters, or facial swelling.
People with a sulfa allergy might experience similar allergic reactions, including rash, with Symtuza. Make sure your healthcare team knows about all of your medication allergies, especially if they're severe.
Taking Symtuza can cause your body to have an intense immune response called immune reconstitution syndrome. Your immune system becomes stronger and more active once you start taking Symtuza to treat HIV. Your immune system then begins to fight off any infections that it was too weak to defend against before you started treatment. This intense immune response can lead to a lot of inflammation.
In rare cases, your immune system can become so strong that it starts to attack healthy cells in your body, leading to certain autoimmune problems. These autoimmune problems can appear as early as during the first few weeks of treatment or many months later.
Tell your healthcare team if you have a fever, difficulty breathing, cough, or any new, unusual symptoms, such as sweating more or hair loss, after you start Symtuza. These might be signs and symptoms of immune reconstitution syndrome and its complications.
Some people who take Symtuza have had kidney problems as early as two weeks after starting treatment. To prevent kidney injury, it's recommended that you avoid taking other medications that can also harm the kidneys, like high doses of nonsteroidal anti-inflammatory drugs (NSAIDs).
Before starting Symtuza, your healthcare team will order blood work or urine tests to check on your kidneys. They'll continue to check periodically during treatment. Let your care team know right away if you experience swelling, muscle pain, or general weakness that don't go away. These might be signs of kidney problems.
In some rare cases, people who take HIV medications, such as Symtuza, can notice changes in body fat. These changes include fat buildup in the back of the neck, breast, and around the middle of the body. Some people also lost fat from the legs, arms, and face. It's not clear whether Symtuza causes these changes to body fat, why this happens, and whether it'll affect your health in the future. Let your healthcare team know if these changes occur while you're taking Symtuza.
Some people with a bleeding condition called hemophilia have had more bleeding after they started taking protease inhibitors, including Symtuza. In about half of the reported cases, people could continue to take this medication after the bleeding stops. It's not clear whether taking Symtuza was related to having more bleeding episodes.
Tell your care team if you have bleeding episodes more often while you're taking Symtuza. Contact your care team right away if you have pain and swelling in your joints or bruising on your skin. These can be signs that blood has built up under the skin or in your joints.
Symtuza can interact with many medications. Some drug interactions, such as with certain other HIV medications or anti-seizure medications, can make Symtuza work less well. This can make it more likely for HIV to spread and become harder to treat. Other types of drug interactions can raise your risk for side effects.
Because of the potential for drug interactions with Symtuza, tell your healthcare team about all the medications you take or plan to take. They can make sure your medications are safe to take together.
| Dosage | Quantity | Price as low as | Price per unit |
|---|---|---|---|
| 800mg/150mg/200mg/10mg | 30 tablets | $4,574.99 | $152.50 |
Each Symtuza tablet contains 800 mg of darunavir, 150 mg of cobicistat, 200 mg of emtricitabine, and 10 mg of tenofovir alafenamide)
Adults and children who weigh at least 88 pounds: The typical dose is 1 tablet by mouth once daily with food.
Contraindications are specific health conditions or situations in which a person should not take a medication due to safety concerns. If you have any of the following conditions or if any of the following apply to you, let your healthcare provider know because Symtuza will not be safe for you to take.
Treatment of HIV infection in adults and children weighing at least 30 lbs, and: